(Bloomberg) -- The head of the US Food and Drug Administration said the agency will “take a hard look” at a gene therapy from ...

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.

Sarepta Therapeutics was approached for comment by Clinical Trials Arena but did not respond before publication. This comes ...

The U.S. Food and Drug Administration will request Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...

A third patient has died from acute liver failure after receiving a gene therapy treatment from Sarepta Therapeutics, the biotech company confirmed to Bloomberg on July 18. The patient died while ...

While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of ...